Related Experiment Video
Updated: May 26, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Recent advances in antiretroviral treatment and prevention in HIV-infected patients
Fernando Maltêz1, Manuela Doroana, Teresa Branco
1Infectious Diseases Service - H. Curry Cabral, Lisbon, Portugal. fmaltez@hccabral.min-saude.pt
Purpose Of Review:
To discuss new antiretroviral agents (ARVs) and alternative ARV treatment strategies that are currently being evaluated, and to provide an overview of the most recent advances in HIV vaccine development.
Recent Findings:
There is a continuous need for improvements in ARV therapy (ART) and several new ARVs are currently undergoing clinical investigation, including the non-nucleoside reverse transcriptase inhibitor rilpivirine, the integrase inhibitor elvitegravir, the chemokine receptor 5 co-receptor antagonist vicriviroc and the maturation inhibitor bevirimat. Strategies to optimize ART, such as treatment interruption, induction-maintenance and class-sparing regimens, are also being evaluated and have had varying success to date. However, vaccination still remains the optimal solution, and one second-generation preventative HIV vaccine has produced encouraging results in a recent phase III trial.
Summary:
Global prevention and treatment with ARVs that are effective, well tolerated and have high barriers to the development of HIV resistance are the main strategies to fight HIV/AIDS while we await the development of an effective vaccine.
More Related Videos
Related Concept Videos
Retrovirus Life Cycles
Sexually Transmitted Infections
Inhibitors of Viral Protein Synthesis
Retroviruses
Healthcare Associated Infections II: Preventive Measures
The best practices for preventing healthcare-associated infections include hand hygiene, patient risk...

